Hansa Biopharma expects to publish its report for Q1 on Thursday, April 20th. On that occasion, HC Andersen Capital will be hosting a digital event on Monday, April 24th at 13.00 where you will be able to meet Head Of Investor Relations Klaus Sindahl who will review highlights from the report and the quarter in general, and take questions.
At the event, you can expect an update on the commercialization of Idefirix in Europe where Hansa Biopharma continues to announce new reimbursement agreements in individual European countries to support the roll-out of Idefirix – the latest one in Spain. You can also expect to get a pipeline update regarding the imlifidase technology platform that holds great potential in several other indications than transplantations such as autoimmune deceases, gene therapy, and oncology. Lastly, you will get an update on the current progress of enrollment of patients to the pivotal ConfIdeS clinical trial in the US that will pave the way for the approval and selling of Idefirix into the US transplantation-market. Enrollment to ConfIdeS is expected to be completed in the first half of 2023.
Disclaimer: HC Andersen Capital receives payment from Hansa Biopharma for a DigitalIR/Corporate Visibility agreement. /Claus Thestrup 10:42 AM 12th of April 2023.
